DS-2741a / Daiichi Sankyo - LARVOL DELTA

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1; N=8; Terminated; Sponsor: Daiichi Sankyo Co., Ltd.; N=75 ➔ 8; Active, not recruiting ➔ Terminated; Company decision of termination of the clinical program.

Clinical • Enrollment change • Trial termination • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (EBMT 2020) - "DS-2741a, inhibited activities of each effector T cell subset, and its inhibitory potency was comparable to that of tacrolimus. Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus."

Aplastic Anemia • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Primary Immunodeficiency • FOXP3 • IL2RA

[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (EBMT 2020) - "DS-2741a, inhibited activities of each effector T cell subset, and its inhibitory potency was comparable to that of tacrolimus. Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus."

Aplastic Anemia • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Primary Immunodeficiency • FOXP3 • IL2RA

[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (EBMT 2020) - "DS-2741a, inhibited activities of each effector T cell subset, and its inhibitory potency was comparable to that of tacrolimus. Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus."

Aplastic Anemia • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Oncology • Primary Immunodeficiency • FOXP3 • IL2RA

[VIRTUAL] DS-2741A, ANTI-ORAI1 ANTIBODY, SHOWED IDEAL PROFILE OF IMMUNOSUPPRESSANT FOR GVHD TREATMENT BY BIASED INHIBITION ON EFFECTOR T CELLS WITHOUT AFFECTING REGULATORY T CELLS FUNCTION (EBMT 2020) - "DS-2741a, inhibited activities of each effector T cell subset, and its inhibitory potency was comparable to that of tacrolimus. Unlike tacrolimus, DS-2741a didn't inhibit Treg cell differentiation and Teff suppression activity. DS-2741a prevented aGvHD in the mouse model with comparable or superior potency to that of Tacrolimus."

Aplastic Anemia • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Primary Immunodeficiency • FOXP3 • IL2RA

Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation. (PubMed, FASEB Bioadv) - "Furthermore, DS-2741a ameliorated house dust mite antigen-induced dermatitis in the human ORAI1 knock-in mouse. Taken together, DS-2741a inhibited T-cell and mast cell functions, thus improving skin inflammation in animal models of atopic dermatitis and reinforcing the need for investigation of DS-2741a for the treatment of allergic diseases in a clinical setting."

Journal • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1; N=75; Active, not recruiting; Sponsor: Daiichi Sankyo Co., Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis (clinicaltrials.gov) - P1; N=75; Recruiting; Sponsor: Daiichi Sankyo Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Newly added product (clinicaltrials.gov) - P1, Atopic Dermatitis, Dermatology

Pipeline update